Hôpitaux Civils de Colmar
Colmar, 68024, France
Location status: Recruiting
Location contact
Emilie Hutt
SUB_INVESTIGATOR
Karine Demesmay
CONTACT
+33389124963 ext. +33
Karine Demesmay
PRINCIPAL_INVESTIGATOR
Magali Eyriey
CONTACT
NCT Number: NCT07779135
The main objective of this study is to describe the effect of an essential oil-based blend applied topically in the management of painful symptoms, sensory disturbances, or functional impairment caused by Chemotherapy-Induced Neuropathy (CIN) in breast cancer patients who have undergone paclitaxel treatment.
Interested in participating?
Request Info18 year and older
Female
Observational
Colmar, 68024, France
Location status: Recruiting
Emilie Hutt
SUB_INVESTIGATOR
Karine Demesmay
CONTACT
+33389124963 ext. +33
Karine Demesmay
PRINCIPAL_INVESTIGATOR
Magali Eyriey
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At enrollment, Day 7 and Day 30 follow-up
The CIPN20 (Chemotherapy-Induced Peripheral Neuropathy) questionnaire is a 20-item questionnaire used to assess and monitor symptoms, specifically targeting chemotherapy-induced neuropathies.
We will limit ourselves to items 31 through 44, which concern sensory and pain-related symptoms.
Items 31-36, 39, and 40 address sensory symptoms and problems. Items 37, 38, 41-44 address motor symptoms and problems. The individual items should be scored such that higher scores represent more symptoms/problems (i.e., higher score = worse).
Time frame: At enrollment, Day 7 and Day 30 follow-up
The EORTC QLG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients.
The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: At Day 7 and Day 30 follow-up
The patient's perceived health status will be assessed using the Patients' Global Impression of Change questionnaire (PGI-C). PGI-C is the PRO counterpart to the Clinical Global Impressions scale, (CGI), which was published in 1976 by the National Institute of Mental Health (US). PGI-C is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved" (1 point), "much improved" (2 points), "minimally improved" (3 points), "no change" (4 points), "minimally worse" (5 points), "much worse" (6 points) or "very much worse" (7 points).
Time frame: At enrollment, Day 7 and Day 30 follow-up
The HAD Scale is a tool used to screen for anxiety and depressive disorders. It consists of 14 items scored on a scale of 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), resulting in two scores (maximum score for each = 21).
Time frame: At Day 7 and Day 30 follow-up
A survey on satisfaction, adherence and adverse events will be conducted using a specific qualitative questionnaire that employs a Likert scale for certain items (acceptance, satisfaction).
For acceptance, a 4-point scale of likert will be used : 1 = "Strongly agree", 2 = "Agree", 3 = "Disagree", 4 = "Strongly disagree".
For overall satisfaction, a 6-point scale will be used, ranging from 1 (very dissatisfied) to 6 (very satisfied).
Contact information is provided by the study sponsor or research team.
Centre Hospitalier de Colmar
Other
Effect of Aromatherapy on the Management of Chemotherapy-Induced Neuropathy (CIN) in Patients Receiving Taxane Therapy for Breast Cancer.
Acronym: AROMA NEUROTAX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06441890
Breast Cancer, Breast Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06774963
Adnexal Diseases, Advanced or Metastatic Solid Tumors
Newport Beach, California, United States
View Trial DetailsNCT06536881
Breast Cancer, Breast Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07524114
Breast Cancer, Breast Diseases
Toronto, Ontario, Canada
View Trial Details